Yondelis for Liposarcoma or Leiomyoscarcoma – Details


( Last Updated : August 22, 2016)
Generic Name:
Trabectedin
Project Status:
Complete
Therapeutic Area:
Metastatic Liposarcoma or Leiomyosarcoma
Manufacturer:
Janssen Inc.
Brand Name:
Yondelis
Project Line:
Reimbursement Review
Project Number:
PC0071-000
NOC Date:

Details


Strength:
1mg/vial
Tumour Type:
Sarcoma
Indications:
Metastatic Liposarcoma or Leiomyosarcoma
Funding Request:
For the treatment of patients with metastatic liposarcoma or leiomyosarcoma after failure of prior anthracycline and ifosfamide chemotherapy
Review Status:
Complete
Sponsor:
Janssen Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.